The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.
Mutations of c-KIT causing spontaneous activation of the KIT receptor kinase are associated with sporadic adult human mastocytosis (SAHM) and with human gastrointestinal stromal tumors. We have classified KIT-activating mutations as either "enzymatic site" type (EST) mutations, affecting the structure of the catalytic portion of the kinase, or as "regulatory" type (RT) mutations, affecting regulation of an otherwise normal catalytic site. Using COS cells expressing wild-type or mutant KIT, 2 compounds, STI571 and SU9529, inhibited wild-type and RT mutant KIT at 0.1 to 1 microM but did not significantly inhibit the Asp816Val EST mutant associated with SAHM, even at 10 microM. Using 2 subclones of the HMC1 mast cell line, which both express KIT with an identical RT mutation but which differ in that one also expresses the Asp816Val EST mutation, both compounds inhibited the RT mutant KIT, thereby suppressing proliferation and producing apoptosis in the RT mutant-only cell line. Neither compound suppressed activation of Asp816Val EST mutant KIT, and neither produced apoptosis or significantly suppressed proliferation of the cell line expressing the Asp816Val mutation. These studies suggest that currently available KIT inhibitors may be useful in treating neoplastic cells expressing KIT activated by its natural ligand or by RT activating mutations such as gastrointestinal stromal tumors but that neither compound is likely to be effective against SAHM. Furthermore, these results help establish a general paradigm whereby classification of mutations affecting oncogenic enzymes as RT or EST may be useful in predicting tumor sensitivity or resistance to inhibitory drugs.
Ma
Yongsheng
Y
Department of Dermatology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Zeng
Shan
S
Metcalfe
Dean D
DD
Akin
Cem
C
Dimitrijevic
Sasa
S
Butterfield
Joseph H
JH
McMahon
Gerald
G
Longley
B Jack
BJ
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001549:Benzamides; D020134:Catalytic Domain / Q000235:genetics; D002455:Cell Division / Q000187:drug effects; D004351:Drug Resistance / Q000235:genetics; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D000068877:Imatinib Mesylate; D008407:Mast Cells / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D008415:Mastocytosis / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology; D020125:Mutation, Missense; D010770:Phosphotransferases / Q000037:antagonists & inhibitors / Q000235:genetics; D010879:Piperazines / Q000494:pharmacology; D019009:Proto-Oncogene Proteins c-kit / Q000187:drug effects / Q000235:genetics*; D011743:Pyrimidines / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D010770:Phosphotransferases; D019009:Proto-Oncogene Proteins c-kit